Kosan opens TIME-1 pivotal trial of tanespimycin in myeloma

Kosan opens TIME-1 pivotal trial of tanespimycin in myeloma

February 1, 2008

Publication

Article

Oncology NEWS InternationalOncology NEWS International Vol 17 No 2

Volume 17

Issue 2

Kosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment

HAYWARD, CaliforniaKosan Biosciences Incorporated has announced that the Tanespimycin in Myeloma Evaluation (TIME-1) pivotal phase III trial for its Hsp90 inhibitor tanespimycin as a potential treatment for multiple myeloma is open for enrollment. Approximately 470 patients with first-relapse disease will be randomized to treatment with bortezomib (Velcade) plus tanespimycin or bortezomib alone.

Articles in this issue

NLST article not balanced, critic of screening trial asserts

M.D. Anderson and AstraZeneca form neuropathic pain alliance

Good nilotinib responses in imatinib-resistant AP-CML

Virus linked to Merkel cell carcinoma

Benefit of adjuvant RT/CT for pancreatic ca affirmed

Recurrence Score helps select node+ pts for chemo

For resectable liver mets: Preop chemotherapy or not?

Plerixafor boosts stem cell mobilization in myeloma pts

MRI shows second-hand smoke damage

Assay has high sensitivity for hard-to-detect SLN mets

Dasatinib effective in imatinib resistant/intolerant CML

ONI remembers Judah Folkman, founder of angiogenesis

New machine approved for adaptive RT

ONI sits down with Dr. Vincent DeVita

Making faster, better, more cost-effective clinical trials

Related Content

Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.

Linvoseltamab Yields High Response in Newly Diagnosed Multiple Myeloma

Sabrina Serani

December 8th 2025

Article

Linvoseltamab monotherapy achieved minimal residual disease negativity in 95% of patients with newly diagnosed multiple myeloma.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD

December 1st 2025

Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

$Results Results from the CAMMA 3 trial showed that subcutaneous cevostamab achieved a 52.0% ORR in BCMA-naive relapsed or refractory multiple myeloma.from the CAMMA 3 trial showed that subcutaneous cevostamab achieved a 52.0% ORR and greater durability BCMA-naive relapsed or refractory multiple myeloma.$